ADE and dengue vaccination
Related Experiment Video
Updated: Feb 28, 2026
A Simple Flow Cytometry Based Assay to Determine In Vitro Antibody Dependent Enhancement of Dengue Virus Using Zika Virus Convalescent Serum
Published on: April 10, 2018
Ruth Aralí Martínez-Vega1, Gabriel Carrasquila2, Expedito Luna3
1Universidad Industrial de Santander, Bucaramanga, Colombia.
Abstract:
The vaccine against Dengue virus (DENV), Dengvaxia® (CYD), produced by Sanofi-Pasteur, has been registered by several national regulatory agencies; nevertheless, the performance and security of this vaccine have been challenged in a series of recent papers. In this work, we intend to contribute to the debate by analyzing the concept of an enhancing vaccine, presenting objections to the epidemiological model base of the concept and, likewise, presenting data that contradict that concept.
